In this section

Filter by year:
Back

News & events

Loading loading...

  • BioFocus DPI and ZoBio announce marketing agreement


    Thu 13 Nov 2008
    BioFocus DPI and ZoBio announced today that they have signed a worldwide marketing and sales agreement for ZoBio’s fragment-based NMR technologies. Under the terms of the agreement BioFocus DPI will sell ZoBio’s services either as a standalone offering or in combination with BioFocus DPI’s drug discovery offering.

  • Galapagos sells San Diego chemistry facility to ChemVentures


    Wed 05 Nov 2008
    Mechelen, Belgium; 5 November 2008 – Galapagos NV (Euronext: GLPG) announces today that it has completed the sale of its BioFocus DPI chemistry facility in San Diego to ChemVentures Pty Ltd, an Australian discovery research group. Financial terms were not disclosed.

  • Galapagos and CHDI enter new collaboration agreements


    Wed 29 Oct 2008
    Mechelen, Belgium and Los Angeles, USA; 29 October 2008 – Galapagos NV (Euronext: GLPG) and CHDI Foundation, Inc., a non-profit organization pursuing treatments for Huntington’s disease (HD), announced today new collaboration agreements focused on developing novel assays for drug discovery and evaluating known compounds as potentially new therapeutic approaches for HD.

  • Enhanced decision support software streamlines data access and integration


    BioFocus DPI releases new version of StarDrop
    Wed 08 Oct 2008
    BioFocus DPI has released an enhanced version of its StarDrop software for guiding decisions in drug discovery. StarDrop 4.2 allows users to directly access data from multiple sources and to interface with other industry standard informatics platforms such as Pipeline Pilot®. By placing StarDrop at the centre of the drug discovery process and applying its unique approach for identifying high quality chemistry, users can maximize the likelihood of success.

  • BioFocus DPI launches seven new libraries including its first libraries targeting proteases


    Wed 24 Sep 2008
    BioFocus DPI announces the launch of seven new biologically-targeted libraries of novel drug-like compounds. These libraries specifically target ion channels, kinases and for the first time, proteases – three of the most important protein classes for drug discovery.

  • Cutting-edge meeting on ion channel drug discovery


    Innovative technology unlocks a challenging target class
    Wed 17 Sep 2008
    The latest technology in ion channel drug discovery will be discussed at a two-day meeting to be held at the Nucleus Conference Facility – Chesterford Research Park, Saffron Walden, UK, on October 9th and 10th 2008. Jointly organized by BioFocus DPI and Molecular Devices, now part of MDS Analytical Technologies, the meeting will focus on screening technologies such as automated patch-clamp, and how these have revolutionized ion channel research.

  • OneWorld Health and BioFocus DPI expand collaboration to develop new drugs for the treatment of childhood diarrheal diseases


    BioFocus DPI to perform high-throughput screening
    Thu 11 Sep 2008
    BioFocus DPI, the service division of Galapagos, and the Institute for OneWorld Health, a non-profit pharmaceutical company, announced today that it had expanded its 2006 collaboration in diarrheal disease drug discovery.

  • BioFocus DPI adds structural biology to its drug discovery services


    Tue 26 Aug 2008
    Galapagos NV and Sareum Holdings plc announce today that Galapagos has acquired Sareum’s assets in drug discovery services, for a total cash consideration of €695,000 (£553,000). These assets will expand and strengthen Galapagos’ service division, BioFocus DPI, by adding structural biology to its pre-clinical drug discovery capabilities.

  • UCB transfers UK-based medicinal chemistry program to BioFocus DPI


    Tue 12 Aug 2008
    Galapagos NV (Euronext: GLPG) announced today that its service division BioFocus DPI and UCB have signed a contract for the provision of chemistry services in the UK by BioFocus DPI, for one of UCB’s medicinal chemistry programs. The total contract value for Galapagos could potentially exceed €4M.

  • BioFocus DPI transfers predictive drug discovery databases to EMBL’s European Bioinformatics Institute


    Wed 23 Jul 2008
    Wellcome Trust grant makes data publicly available to researchers BioFocus DPI announces the transfer of its databases for predictive drug discovery to the EMBL’s European Bioinformatics Institute (EMBL-EBI). The data will become publicly available on-line to drug discovery researchers worldwide through the EMBLEBI under license from Galapagos, BioFocus DPI’s parent company.



Bookmark with:

What are these?


Print to HTML Print as PDF Send to a friend


Related links


Get in contact with us









Where to find usSubscribe to the RSS feed

view all events

 


BioFocus®, SoftFocus®, Galapagos®, SilenceSelect® and FLeXSelect® ThemePair™, FieldFocus™, HDRA™. Helical Domain Recognition Analysis™, 2D Roadmap™, Thematic Analysis™, SFK™, SFI™, SFG™ and PrimePath™ are trademarks of Galapagos NV and/or its affiliates.